Literature DB >> 6101980

Effects of changes in the structure of enkephalins and of narcotic analgesic drugs on their interactions with mu- and delta-receptors.

H W Kosterlitz, J A Lord, S J Paterson, A A Waterfield.   

Abstract

1 The activity pattern of analogues of the enkephalins was determined in four parallel assays, the inhibition of the electrically evoked contraction of the guinea-pig ileum and mouse vas deferens at 36 degrees C and the inhibition of [(3)H]-naltrexone and [(3)H]-leucine-enkephalin binding at 0 to 4 degrees C in homogenates of guinea-pig brain.2 The activity pattern was best characterized by the ratio of the potency in the guinea-pig ileum to that in the mouse vas deferens (G.p.i./M.v.d.) and the ratio of the potency in inhibiting [(3)H]-naltrexone binding to that in inhibiting [(3)H]-leucine-enkephalin binding (Nal/Leu).3 The enkephalins had low G.p.i./M.v.d. (0.02 to 0.09) and low Nal/Leu (0.05 to 0.18) ratios whereas the corresponding values for morphine were 7.0 and 7.5.4 Analogues obtained by substituting D-Ala for Gly(2) and D-Met or D-Leu for L-Met(5) or L-Leu(5) showed only minor changes in G.p.i./M.v.d. (0.01 to 0.11) and in Nal/Leu (0.06 to 0.13) ratios.5 Analogues in which resistance to enzymatic degradation was brought about by amidation of the C-terminal carboxylic group or methylation of the amino group of tyrosine or both modifications, had G.p.i./M.v.d. ratios of 1.2 to 5.5 and Nal/Leu ratios of 0.5 to 21. High values (2.1 and 3.4) were found for the potent antinociceptive analogue of Sandoz, Tyr-D-Ala-Gly-NCH(3)Phe-Met(O)-ol.6 In the mouse vas deferens, some of the analogues with high G.p.i./M.v.d. and Nal/Leu ratios were tested for antagonism by naloxone and found to require less than the high concentration needed for the natural enkephalins. C57/BL mice, which have a lowered sensitivity to morphine but a normal response to peptides with low G.p.i./M.v.d. and Nal/Leu ratios, had a lowered sensitivity to analogues with high ratios.7 In the alkaloid-like series of narcotic analgesic drugs, ketobemidone, levorphanol, methadone, etorphine and the antagonist Mr 2266 had lower Nal/Leu ratios (1.0 to 2.8) than morphine, normorphine, naloxone and naltrexone (8 to 12).8 It would appear that compounds with low G.p.i./M.v.d. and Nal/Leu ratios interact mainly with delta-receptors in the brain and peripheral nervous system while compounds with high ratios interact mainly with mu-receptors. For antinociceptive action mu-receptors may be more important than delta-receptors.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6101980      PMCID: PMC2043928          DOI: 10.1111/j.1476-5381.1980.tb10422.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  14 in total

1.  A synthetic enkephalin analogue with prolonged parenteral and oral analgesic activity.

Authors:  D Roemer; H H Buescher; R C Hill; J Pless; W Bauer; F Cardinaux; A Closse; D Hauser; R Huguenin
Journal:  Nature       Date:  1977-08-11       Impact factor: 49.962

2.  The opiate receptor binding interactions of 3H-methionine enkephalin, an opioid peptide.

Authors:  R Simantov; S R Childers; S H Snyder
Journal:  Eur J Pharmacol       Date:  1978-02-01       Impact factor: 4.432

3.  Mode of deactivation of the enkephalins by rat and human plasma and rat brain homogenates.

Authors:  J M Hambrook; B A Morgan; M J Rance; C F Smith
Journal:  Nature       Date:  1976-08-26       Impact factor: 49.962

4.  (D-met2, pro5)-enkephalinamide: a potent morphine-like analgesic.

Authors:  J I Székely; A Z Rónai; Z Dunai-Kovács; E Miglécz; I Berzétri; S Bajusz; L Gráf
Journal:  Eur J Pharmacol       Date:  1977-06-01       Impact factor: 4.432

5.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.

Authors:  W R Martin; C G Eades; J A Thompson; R E Huppler; P E Gilbert
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

6.  Differentiation between opioid peptides by naltrexone.

Authors:  A Z Rónai; I Berzétei; S Bajusz
Journal:  Eur J Pharmacol       Date:  1977-10-15       Impact factor: 4.432

7.  Effect of a potent synthetic opioid pentapeptide in some anti-nociceptive and behavioural tests in mice and rats [proceedings].

Authors:  M G Baxter; D Goff; A A Miller; I A Saunders
Journal:  Br J Pharmacol       Date:  1977-03       Impact factor: 8.739

8.  Endogenous opioid peptides: multiple agonists and receptors.

Authors:  J A Lord; A A Waterfield; J Hughes; H W Kosterlitz
Journal:  Nature       Date:  1977-06-09       Impact factor: 49.962

9.  The effects of adrenaline, noradrenaline and isoprenaline on inhibitory alpha- and beta-adrenoceptors in the longitudinal muscle of the guinea-pig ileum.

Authors:  H W Kosterlitz; R J Lydon; A J Watt
Journal:  Br J Pharmacol       Date:  1970-06       Impact factor: 8.739

10.  3H-Leu5-enkephalin specific binding to synaptic membrane-comparison with 3H-dihydromorphine and 3H-naloxone.

Authors:  P Y Law; H H Loh
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1978-09
View more
  34 in total

1.  Dopaminergic amacrine cells express opioid receptors in the mouse retina.

Authors:  Shannon K Gallagher; Julia N Anglen; Justin M Mower; Jozsef Vigh
Journal:  Vis Neurosci       Date:  2012-05       Impact factor: 3.241

2.  Enkephalins modulate inhibitory neuromuscular transmission in circular muscle of human colon via delta-opioid receptors.

Authors:  C H Hoyle; M A Kamm; G Burnstock; J E Lennard-Jones
Journal:  J Physiol       Date:  1990-12       Impact factor: 5.182

3.  Interactions of isamoltane (CGP 361A), an anxiolytic phenoxypropanolamine derivative, with 5-HT1 receptor subtypes in the rat brain.

Authors:  P C Waldmeier; M Williams; P A Baumann; S Bischoff; M A Sills; R F Neale
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-06       Impact factor: 3.000

Review 4.  Sufentanil. A review of its pharmacological properties and therapeutic use.

Authors:  J P Monk; R Beresford; A Ward
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

5.  Conformational characteristics of receptor-selective opioid peptides. 1H n.m.r. and c.d. spectroscopic studies of delta-kephalin and [Val4]morphiceptin.

Authors:  M Doi; M Tanaka; K Ikuma; M Nabae; K Kitamura; M Inoue; T Ishida
Journal:  Biochem J       Date:  1988-04-15       Impact factor: 3.857

6.  Nufenoxole, a new antidiarrhoeal agent, inhibits fluid secretion in the human jejunum.

Authors:  K J Moriarty; D D Rolston; M J Kelly; M Shield; M L Clark
Journal:  Gut       Date:  1985-01       Impact factor: 23.059

7.  The distribution of adrenoceptors and other drug receptors between the two ends of the rat vas deferens as revealed by selective agonists and antagonists.

Authors:  A MacDonald; J C McGrath
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

8.  A method to estimate the potency of the mu-component of an opioid having mixed mu-, and kappa- and/or delta-agonist activities.

Authors:  X F Liu; X T Fan; K Kitamura; T Taniguchi; T Oka
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

9.  Comparison in the mouse of the effect of the opiate delta receptor antagonist ICI 154129 and naloxone in tests of extinction, passive avoidance and food intake.

Authors:  D Benton; J C Dalrymple-Alford; K H McAllister; P F Brain; S Brain
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

10.  Dermorphin-related peptides from the skin of Phyllomedusa bicolor and their amidated analogs activate two mu opioid receptor subtypes that modulate antinociception and catalepsy in the rat.

Authors:  L Negri; G F Erspamer; C Severini; R L Potenza; P Melchiorri; V Erspamer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.